Open this publication in new window or tab >>Midatech Pharma PLC , Cardiff , UK.
Midatech Pharma PLC , Cardiff , UK.
NanoPass Technologies Ltd. , Nes Ziona , Israel.
NanoPass Technologies Ltd. , Nes Ziona , Israel.
School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , UK.
School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , UK.
School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , UK.
Central Biotechnology Services, Cardiff University , Cardiff , UK.
Diabetes Research Group, Cardiff University School of Medicine , Cardiff , UK.
Diabetes Research Group, Cardiff University School of Medicine , Cardiff , UK.
Diabetes Research Group, Cardiff University School of Medicine , Cardiff , UK.
Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University , Swansea , UK.
Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University , Swansea , UK.
Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University , Swansea , UK.
Swansea Trials Unit, Swansea University Medical School , Swansea , UK.
Department of Cellular Pathology, University Hospital of Wales , Cardiff , UK.
Division of Infection & Immunity, Cardiff University School of Medicine , Cardiff , UK.
Welsh Institute of Dermatology, University Hospital of Wales , Cardiff , UK.
Diabetes Research Group, Cardiff University School of Medicine , Cardiff , UK.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Children's and Women's Health. Linköping University, Faculty of Medicine and Health Sciences.
Diabetes Research Group, Cardiff University School of Medicine , Cardiff , UK.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Children's and Women's Health. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center of Paediatrics and Gynaecology and Obstetrics, H.K.H. Kronprinsessan Victorias barn- och ungdomssjukhus.
Show others...
2022 (English)In: Immunotherapy Advances, E-ISSN 2732-4303, Vol. 2, no 1, article id ltac002Article in journal (Refereed) Published
Abstract [en]
Antigen-specific immunotherapy is an immunomodulatory strategy for autoimmune diseases, such as type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop autoimmune β-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human proinsulin peptide C19-A3 (known for its positive safety profile) was conjugated to ultrasmall gold nanoparticles (GNPs), an attractive drug delivery platform due to the potential anti-inflammatory properties of gold. We hypothesised that microneedle intradermal delivery of C19-A3 GNP may improve peptide pharmacokinetics and induce tolerogenic immunomodulation and proceeded to evaluate its safety and feasibility in a first-in-human trial. Allowing for the limitation of the small number of participants, intradermal administration of C19-A3 GNP appears safe and well tolerated in participants with type 1 diabetes. The associated prolonged skin retention of C19-A3 GNP after intradermal administration offers a number of possibilities to enhance its tolerogenic potential, which should be explored in future studies.
Keywords
gold nanoparticle; microneedle; peptide immunotherapy; proinsulin; type 1 diabetes
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:liu:diva-192443 (URN)10.1093/immadv/ltac002 (DOI)
2023-03-172023-03-172023-05-05